Newsletter | November 22, 2021

11.22.21 -- Ensuring Biosafety And Accelerating Biologics Development

 
Rapid Biosafety Testing Enables The Future Of Manufacturing
 

Explore the factors driving the evolution toward faster biosafety testing and rapid approaches for adventitious agent testing that are more aligned with manufacturing trends.

Alternatives To In Vivo Assays For Biosafety Testing Of Biologics
 

Even as alternative methods such as PCR and NGS have emerged, in vivo tests have stubbornly remained a central part of testing. Here, we examine current in vivo methods and explore modern alternatives.

Accelerate CHO Cell Characterization
 

The development of the Blazar™ Rodent Panel allows biopharma to move away from traditional in vivo antibody production assays when characterizing cell banks of rodent origin used in the production of biologicals.

Not Everyone Loves Surprises: Know Your ADC’s Critical Quality Attributes
 

Combatting the challenges of developing and manufacturing ADCs requires robust product characterization throughout all phases of development.

Meet Stability Testing Expectations In A Complex Biopharma Landscape
 

What was once a check-the-box procedure in standard stability testing now requires a deeper understanding of the molecule, how it behaves, and, most importantly, what effect it has on the patient.

How Molecular Structure Influences Potency Of A Therapeutic Biologic
 

Gain an understanding of how an antibody’s molecular structure and its many measurable properties influence its binding and affect potency of a therapeutic biologic.